BioSpace News Archive

Bracco Imaging S.p.A., and Shanghai Hengrui Pharmaceuticals Co. Ltd.,have signed today a collaboration agreement on new R&D activities in China.

The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin).

Healthcare-focused Investment Bank Issues Spring 2018 White Paper on State of the Telehealth Industry

Covalon wins every single Vascular Access dressing category for the next three years in the Gulf Cooperation Council States in the Middle East

LuViva proved to be the more sensitive test, finding cervical cancer missed by Pap and HPV tests.

NanoSomiX, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the company’s first patent covering its groundbreaking proprietary exosome isolation and biomarker detection technology.

- The label update is effective immediately in the United States(1) -

Polaris Partners led the investment and Dave Barrett joins the Board of Directors as the team expands its intelligent data cloud and curated registries for measuring, comparing and predicting health outcomes

- Novel product provides qualified clinicians with the option of non-invasive retrograde flushing of the ventricular catheter, to unblock occluded inlet holes or open a relief membrane to restore or increase cerebrospinal fluid (CSF) flow in a non-flowing shunt - According to The Hydrocephalus Association, at least 50 percent of patients implanted with shunts suffer from shunt failures and blockages within two years, requiring repeated revision surgeries

SomaGenics announced the launch of RealSeq®-biofluids, a next-generation sequencing (NGS) library construction kit sensitive enough to detect small RNAs from cell-free biofluids. Further enhancing its efforts in the liquid biopsy arena, SomaGenics has received a 3-year Phase II SBIR grant from the NIH for the development of RealSeq®-T, a technology enabling extraction-free, targeted NGS of small RNAs directly from biofluids.